Welcome to our dedicated page for ACCENDRA HEALTH INC/VA/ SEC filings (Ticker: ACH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ACCENDRA HEALTH INC/VA/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ACCENDRA HEALTH INC/VA/'s regulatory disclosures and financial reporting.
Kline Teresa L. reported acquisition or exercise transactions in this Form 4 filing.
Accendra Health Inc. director Teresa L. Kline received a grant of 31,191 shares of common stock as equity compensation. The shares were awarded at no cash cost to her and are structured as restricted stock. Following this grant, she directly holds 85,316 common shares.
The restricted stock grant will vest on the earlier of one year from the grant date or the date of the next annual meeting that occurs at least 50 weeks after the grant date, aligning the director’s compensation with shareholder interests over that period.
Klemash Stephen W reported acquisition or exercise transactions in this Form 4 filing.
ACCENDRA HEALTH INC/VA/ director Stephen W. Klemash received a grant of 31,191 shares of Common Stock as a restricted stock award. The grant was awarded at a price of $0.00 per share as part of equity compensation and increased his directly held shares to 90,242.
The restricted stock will vest on the earlier of one year from the grant date or the date of the next annual meeting that is at least 50 weeks after the grant date. This is a compensation-related equity grant rather than an open-market share purchase.
Gardner-Smith Kenneth reported acquisition or exercise transactions in this Form 4 filing.
Accendra Health Inc. director Kenneth Gardner-Smith received a grant of 31,191 shares of Common Stock as restricted stock on May 14, 2026. These shares were awarded at no cash cost and increase his direct holdings to 86,113 shares.
The restricted stock grant vests on the earlier of one year from the grant date or the next annual meeting that is at least 50 weeks after the grant date, meaning the award is tied to continued board service over roughly a one-year period.
Bingham Gwendolyn M reported acquisition or exercise transactions in this Form 4 filing.
Accendra Health director Gwendolyn M. Bingham received a grant of 31,191 phantom stock units on May 14, 2026 at no cost. This award increases her phantom stock holdings to 80,603 units. Each phantom unit is convertible on a 1-for-1 basis into common stock and becomes payable, in cash or common stock at her election, upon events such as death, disability, termination of service as director, or a preselected future delivery date.
Beck Mark A reported acquisition or exercise transactions in this Form 4 filing.
Accendra Health Inc. director Mark A. Beck received a grant of 31,191 shares of common stock as equity compensation. The restricted stock was awarded at no cash cost to him and increases his direct holdings to 71,259 shares.
According to the terms, the restricted stock vests on the earlier of one year from the grant date or the date of the next annual meeting that is at least 50 weeks after the grant date. Until vesting, these shares are subject to forfeiture conditions typically linked to continued board service.
Accendra Health, Inc. reported results from its 2026 Annual Meeting of Shareholders. Shareholders approved the Accendra Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan, which replaces the prior 2023 plan and allows the Board’s Our People & Culture Committee to grant equity and other incentive awards to employees, non-employee directors and consultants.
At the meeting, 76,437,917 shares were entitled to vote and 62,134,133 shares were voted, representing approximately 81.29% participation. Six director nominees each received over 48.7 million votes for, including 51,189,677 votes for Teresa L. Kline, with detailed vote counts and broker non-votes reported for all proposals.
Charles Schwab Investment Management Inc. filed Amendment No. 1 to a Schedule 13G/A reporting beneficial ownership of 3,635,526 shares of Accendra Health Inc. common stock (CUSIP 690732102), representing 4.75% of the class as of 03/31/2026. The filing shows sole voting and sole dispositive power over the same 3,635,526 shares. The amendment is signed by Omar Aguilar on 05/13/2026.
Accendra Health, Inc. reported a net loss from continuing operations of $6.5 million, or $0.08 per share, for the quarter ended March 31 2026, compared with a loss of $3.8 million a year earlier. Net revenue declined 6.8% to $627.8 million, mainly due to terminated contracts with a major commercial payor that represented $37 million, or 6%, of quarterly revenue and nearly all capitation revenue.
Operating income was $17.1 million, helped by a $52 million gain on sales of patient service equipment linked to the payor exit and lower exit and realignment costs, but higher interest expense of $32.3 million pushed results into a loss. Cash flow from operating activities was an outflow of $50.1 million, while cash and cash equivalents increased to $336.9 million after equipment sale proceeds and additional revolver borrowings.
The company remains highly leveraged, with total debt of $2.10 billion against a balance sheet deficit of $464.8 million. A substantial portion of debt, including Term Loan A and the revolving credit facility, is classified as current due to 2027 maturities. Management has obtained creditor commitments for a “Balance Sheet Optimization Transaction” to refinance Term Loan A into new 9.000% senior secured first lien notes due 2032, amend and extend the revolver to 2030, and exchange the 2029 and 2030 unsecured notes into new secured notes, and believes this will provide sufficient liquidity over the next twelve months.
Accendra Health is pursuing a comprehensive balance sheet overhaul built around new secured debt, note exchanges and amended bank facilities. The company agreed to offer $326.25 million of new 9.000% Senior Secured First Lien Notes due 2032, alongside exchange offers and consent solicitations for its existing 4.500% 2029 and 6.625% 2030 senior notes.
Certain noteholders and term loan lenders have committed, subject to conditions, to backstop $261.0 million of the new first lien notes and up to an additional $65.25 million, and to tender all of their existing notes in the exchanges. Revolving lenders have committed to a new $300.0 million revolving credit facility due 2030, and term lenders have agreed to consents and covenant changes, including waiving mandatory prepayments tied to $400.0 million of asset sale proceeds.
The company’s confidential investor deck highlights its post-divestiture profile as a pure‑play home‑based care platform with about $2.8 billion of FY2025 revenue, diversified chronic‑care exposure, and management’s projections for mid‑teens adjusted EBITDA margins, strong free‑cash‑flow generation and lower leverage after the transaction.
Accendra Health reported a first-quarter 2026 net loss from continuing operations of $6.5 million, or $0.08 per share, on net revenue of $627.8 million, down from $673.9 million a year earlier. Operating income was $17.1 million, but higher interest expense contributed to the loss.
Non-GAAP results weakened, with adjusted net loss of $3.1 million versus adjusted net income of $23.2 million and adjusted EBITDA of $58.4 million versus $96.0 million. Free cash flow turned slightly negative at $(2.0) million. Cash rose to $336.9 million, while net debt remained high at $1.77 billion.
The company also announced commitments from existing creditors for a more than $1.5 billion comprehensive balance sheet optimization transaction intended to extend debt maturities, reduce total leverage and reset its capital structure as it continues its shift to a pure play home-based care business.